News & Updates

Adding immunotherapy to the first-line treatment for advanced and metastatic endometrial cancer may significantly improve some oncologic outcomes, particularly within the mismatch repair deficiency/microsatellite instability-hypermutated (MMRd/MSI-H) subset, suggests a study.

A large percentage of patients with relapsed/refractory multiple myeloma (RRMM) respond to the bispecific antibody linvoseltamab, with deep and durable responses seen even in the high-risk subgroups, according to data from the phase I/II LINKER-MM1 trial.

High cognitive reserve appears to confer protection against dementia, even among people with genetic predisposition to dementia, according to a study.